UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...

Does the Simultaneous Introduction of Several Pharmaceuticals in the Post-Lenalidomide Era Translate to Better Outcomes in Relapse Refractory Multiple Myeloma? Findings from the Real-World Innovation in Multiple Myeloma (REAL IMM) Study

Cancers, 2023-12, Vol.15 (24), p.5846

2023

Link zum Volltext

Verfügbarkeit prüfen

Real-world data on Len/Dex combination at second-line therapy of multiple myeloma: treatment at biochemical relapse is a significant prognostic factor for progression-free survival

Annals of hematology, 2018-09, Vol.97 (9), p.1671-1682

2018

Link zum Volltext

Verfügbarkeit prüfen

Clinical features, outcome, and prognostic factors for survival and evolution to multiple myeloma of solitary plasmacytomas: A report of the Greek myeloma study group in 97 patients

American journal of hematology, 2014-08, Vol.89 (8), p.803-808

2014

Link zum Volltext

Verfügbarkeit prüfen

P901: DARATUMUMAB, IXAZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA PRE‐TREATED WITH A LENALIDOMIDE‐BASED REGIMEN: FINAL OUTCOMES OF THE PHASE 2 DARIA STUDY

HemaSphere, 2023-08, Vol.7 (S3), p.e43614c0-n/a

2023

Link zum Volltext

Verfügbarkeit prüfen

Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial

The Lancet (British edition), 2021-06, Vol.397 (10292), p.2361-2371

2021

Link zum Volltext

Verfügbarkeit prüfen

Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial

The lancet oncology, 2021-06, Vol.22 (6), p.801-812

2021

Link zum Volltext

Verfügbarkeit prüfen

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

The lancet oncology, 2019-06, Vol.20 (6), p.781-794

2019

Link zum Volltext

Verfügbarkeit prüfen

Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial

The Lancet (British edition), 2020-11, Vol.396 (10262), p.1563-1573

2020

Link zum Volltext

Verfügbarkeit prüfen

Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma: Reduction post-bortezomib monotherapy

International journal of cancer, 2012-09, Vol.131 (6), p.1466-1471

2012

Link zum Volltext

Verfügbarkeit prüfen

An open-label phase 2 study treating patients with first or second relapse of multiple myeloma with carfilzomib, pomalidomide, and dexamethasone (KPd): SELECT study

Leukemia & lymphoma, 2024-03, p.1-10

2024

Link zum Volltext

Verfügbarkeit prüfen

OCEAN (OP-103): Melflufen Plus Dexamethasone (Dex) Versus Pomalidomide (Pom) and Dex in Relapsed Refractory Multiple Myeloma (RRMM) - Renal Impairment (RI) Analysis

Blood, 2021-11, Vol.138 (Supplement 1), p.4777-4777

2021

Link zum Volltext

Verfügbarkeit prüfen

Safety and Efficacy of Daratumumab with Ixazomib and Dexamethasone in Patients with One Prior Lenalidomide-Based Regimen: Outcomes of the Phase 2 Daria Study

Blood, 2021-11, Vol.138 (Supplement 1), p.2737-2737

2021

Link zum Volltext

Verfügbarkeit prüfen

A phase 3, open-label, randomized study to evaluate the efficacy and safety of single-agent belantamab mafodotin (belamaf) compared to pomalidomide plus low-dose dexamethasone (Pd) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): DREAMM-3

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.8007-8007

2023

Link zum Volltext

Verfügbarkeit prüfen

Subgroup analysis of ICARIA‐MM study in relapsed/refractory multiple myeloma patients with high‐risk cytogenetics

British journal of haematology, 2021-07, Vol.194 (1), p.120-131

2021

Link zum Volltext

Verfügbarkeit prüfen

Survey of the Relevance of Quality of Life (QoL) Questionnaires (QoLQs) Currently Used to Evaluate Multiple Myeloma (MM) Patients' Qol in Real-World MM Patients and Healthcare Professionals (HCPs)

Blood, 2022-11, Vol.140 (Supplement 1), p.12506-12507

2022

Link zum Volltext

Verfügbarkeit prüfen

Multiple myeloma triplet therapies: baseline characteristics and control groups – Authors' reply

The Lancet (British edition), 2021-05, Vol.397 (10285), p.1621-1623

2021

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of daratumumab with ixazomib and dexamethasone in lenalidomide‐exposed patients after one prior line of therapy: Final results of the phase 2 study DARIA

American journal of hematology, 2024-03, Vol.99 (3), p.396-407

2024

Link zum Volltext

Verfügbarkeit prüfen

CAMMA 3: A multicenter phase Ib trial evaluating the safety, pharmacokinetics, and activity of subcutaneous cevostamab monotherapy in patients with relapsed or refractory multiple myeloma

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS8070-TPS8070

2022

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 116

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(116)
Mit Volltextzugriff
(115)

Publikationsform

Artikel
(116)

Sprache

Englisch
(116)
Japanisch
(4)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenström macroglobulinemia: final analysis of a phase 2 study

Does the Simultaneous Introduction of Several Pharmaceuticals in the Post-Lenalidomide Era Translate to Better Outcomes in Relapse Refractory Multiple Myeloma? Findings from the Real-World Innovation in Multiple Myeloma (REAL IMM) Study

Real-world data on Len/Dex combination at second-line therapy of multiple myeloma: treatment at biochemical relapse is a significant prognostic factor for progression-free survival

Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma

Clinical features, outcome, and prognostic factors for survival and evolution to multiple myeloma of solitary plasmacytomas: A report of the Greek myeloma study group in 97 patients

Daratumumab Improves Bone Turnover in Relapsed/Refractory Multiple Myeloma; Phase 2 Study "REBUILD"

P901: DARATUMUMAB, IXAZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA PRE‐TREATED WITH A LENALIDOMIDE‐BASED REGIMEN: FINAL OUTCOMES OF THE PHASE 2 DARIA STUDY

P897: EVALUATION OF THE PROGNOSTIC IMPACT OF SECOND LINE ANTI‐MYELOMA TREATMENTS ON POST‐ PROGRESSION OUTCOMES IN THE REAL‐WORLD SETTING: THE GREEK MYELOMA STUDY GROUP EXPERIENCE

P920: EVALUATION OF EARLY PROGRESSIVE DISEASE (EPD) IN NEWLY DIAGNOSED MYELOMA PATIENTS AND IDENTIFICATION OF PROGNOSTIC FACTORS IN THE ERA OF MODERN THERAPIES. THE GREEK MYELOMA STUDY GROUP EXPERIENCE

S199: A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY EVALUATING THE EFFICACY AND SAFETY OF SINGLE AGENT BELANTAMAB MAFODOTIN VS POMALIDOMIDE PLUS DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (DREAMM-3)

Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial

Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial

Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma: Reduction post-bortezomib monotherapy

An open-label phase 2 study treating patients with first or second relapse of multiple myeloma with carfilzomib, pomalidomide, and dexamethasone (KPd): SELECT study

OCEAN (OP-103): Melflufen Plus Dexamethasone (Dex) Versus Pomalidomide (Pom) and Dex in Relapsed Refractory Multiple Myeloma (RRMM) - Renal Impairment (RI) Analysis

Safety and Efficacy of Daratumumab with Ixazomib and Dexamethasone in Patients with One Prior Lenalidomide-Based Regimen: Outcomes of the Phase 2 Daria Study

A phase 3, open-label, randomized study to evaluate the efficacy and safety of single-agent belantamab mafodotin (belamaf) compared to pomalidomide plus low-dose dexamethasone (Pd) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): DREAMM-3

Subgroup analysis of ICARIA‐MM study in relapsed/refractory multiple myeloma patients with high‐risk cytogenetics

S199: A PHASE 3, OPEN‐LABEL, RANDOMIZED STUDY EVALUATING THE EFFICACY AND SAFETY OF SINGLE AGENT BELANTAMAB MAFODOTIN VS POMALIDOMIDE PLUS DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (DREAMM‐3)

Survey of the Relevance of Quality of Life (QoL) Questionnaires (QoLQs) Currently Used to Evaluate Multiple Myeloma (MM) Patients' Qol in Real-World MM Patients and Healthcare Professionals (HCPs)

Multiple myeloma triplet therapies: baseline characteristics and control groups – Authors' reply

Efficacy and safety of daratumumab with ixazomib and dexamethasone in lenalidomide‐exposed patients after one prior line of therapy: Final results of the phase 2 study DARIA

CAMMA 3: A multicenter phase Ib trial evaluating the safety, pharmacokinetics, and activity of subcutaneous cevostamab monotherapy in patients with relapsed or refractory multiple myeloma

Suchergebnisse filtern